Late-onset delayed excretion of methotrexate

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 2, 2004, Pages 146-152

  Pauley, Jennifer L ^a   Panetta, John Carl ^a   Schmidt, Jeffrey ^a   Kornegay, Nancy ^a   Relling, Mary V ^a,b   Pui, Ching Hon ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Methotrexate; Pharmacokinetics; Pleural effusion; Renal dysfunction; Third space

Indexed keywords

ADRENALIN; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; ASPARAGINASE; CYCLOBENZAPRINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOPAMINE; FOLINIC ACID; GLUCOCORTICOID; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MEROPENEM; METHOTREXATE; MONOCLONAL ANTIBODY; MORPHINE; NORADRENALIN; PREDNISONE; TOBRAMYCIN; VANCOMYCIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; ASCITES; BACKACHE; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG MONITORING; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MUCOSA INFLAMMATION; NAUSEA; PLEURA EFFUSION; PLEURISY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 3843092805     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0797-y     Document Type: Article

References (8)

1. Chan H, Evans WE, Pratt CB (1977) Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treat Rep 61:797
2. D'Argenio DZ, Schumitzky A (1997) ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles
3. Evans WE, Pratt CB (1978) Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 23:68
4. Li J, Gwilt P (2002) The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 50:373
5. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97:73
6. Panetta JC, Yanishevski Y, Pui CH, Sandlund JT, Rubnitz J, Rivera GK, Ribeiro R, Evans WE, Relling MV (2002) A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 50:419
7. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui CH, Evans WE (1994) Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996
8. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B (1974) Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 34:3487